L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.82 NOK -1.16% Market Closed
Market Cap: 338.3m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Wall Street
Price Targets

LYTIX Price Targets Summary
Lytix Biopharma AS

Wall Street analysts forecast LYTIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYTIX is 16.32 NOK with a low forecast of 16.16 NOK and a high forecast of 16.8 NOK.

Lowest
Price Target
16.16 NOK
137% Upside
Average
Price Target
16.32 NOK
139% Upside
Highest
Price Target
16.8 NOK
146% Upside
Lytix Biopharma AS Competitors:
Price Targets
ABBV
Abbvie Inc
20% Upside
RXRX
Recursion Pharmaceuticals Inc
36% Upside
LVTX
LAVA Therapeutics NV
320% Upside
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
153% Upside
BIIB
Biogen Inc
59% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
10% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
26% Upside
CTMX
CytomX Therapeutics Inc
421% Upside

Revenue
Forecast

Revenue Estimate
Lytix Biopharma AS

For the last 5 years the compound annual growth rate for Lytix Biopharma AS's revenue is 64%. The projected CAGR for the next 2 years is 423%.

64%
Past Growth
423%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Lytix Biopharma AS

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Lytix Biopharma AS

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LYTIX's stock price target?
Price Target
16.32 NOK

According to Wall Street analysts, the average 1-year price target for LYTIX is 16.32 NOK with a low forecast of 16.16 NOK and a high forecast of 16.8 NOK.

What is Lytix Biopharma AS's Revenue forecast?
Projected CAGR
423%

For the last 5 years the compound annual growth rate for Lytix Biopharma AS's revenue is 64%. The projected CAGR for the next 2 years is 423%.

Back to Top